Immutep (ASX:IMM; NASDAQ:IMMP) has announced preliminary topline results from Cohort B of the TACTI-003 Phase IIb trial. The trial evaluates efti in combination with MSD’s anti-PD-1 therapy KEYTRUDA® ...
Source LinkImmutep (ASX:IMM; NASDAQ:IMMP) has announced preliminary topline results from Cohort B of the TACTI-003 Phase IIb trial. The trial evaluates efti in combination with MSD’s anti-PD-1 therapy KEYTRUDA® ...
Source Link
Comments